Lerociclib (Lerocliclib)
Breast Cancer
Key Facts
About Chemogenics BioPharma
ChemoGenics BioPharma operates as a preclinical-stage contract research organization (CRO) and drug discovery partner, offering a full suite of services from custom synthesis and medicinal chemistry to in vitro ADME and in vivo PK/PD studies. The company's core strength lies in its team of PhD scientists with over 10+ years of industry experience, enabling them to deliver intellectual property and support clients from target identification to clinical candidate selection. While primarily a service provider, the company's leadership has a proven track record in drug discovery, having invented the commercially marketed CDK4/6 inhibitor Trilaciclib and advanced Lerociclib to Phase 3 trials. Their strategic focus is on being a cost-effective, one-stop partner for managing escalating R&D costs while protecting client IP.
View full company profileOther Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Verzenio (abemaciclib) | Eli Lilly | Approved |
| Pan-mutant-selective PI3Kα inhibitor | Novartis | Acquisition |
| Trodelvy | Royalty Pharma | Commercial |
| Trastuzumab biosimilar (IBI306) | Innovent Biologics | Phase 3 |
| Ogivri (trastuzumab biosimilar) | Viatris | Approved |
| Trastuzumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| Biosimilar Trastuzumab | Cipla | Commercial |
| Ogivri (Trastuzumab) | Biocon | Approved |
| Tamoxifen | Natco Pharma | Approved |
| ARV-027 | Arvinas | Phase 1 |
| Prognostic Genomic Tests | Eurobio Scientific | Commercial |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |